Legal status · 2026

Is Compounded Tirzepatide Legal in 2026?

A patient guide to the federal compounding pathway for tirzepatide — Section 503A and Section 503B of the FD&C Act, what the April 2026 FDA action changed, and how reputable telehealth programs continue to operate.

503A & 503B pathways legal
FDA April 2026 proposal active
Public comment closes June 29 2026
Updated May 27, 2026
Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

The compounding statute, in plain English

The Federal Food, Drug, and Cosmetic Act includes two sections that establish the legal framework for compounded medications in the United States:

When tirzepatide entered the FDA Drug Shortage list (resolved October 2024), the compounding pathway expanded to address documented unmet patient need. After the shortage resolved, the regulatory environment around mass-marketed compounded GLP-1 medications tightened. The April 2026 FDA action is the latest step in that tightening.

What the April 2026 FDA proposal actually does

The April 30, 2026 Federal Register notice (docket 2026-08552) proposes updates to the FDA 503B Bulks List — the list of bulk drug substances that 503B outsourcing facilities are permitted to use in compounding. Public comment closes June 29, 2026. See our full news roundup for the link to the FDA primary source.

Crucially, the proposal does not:

How to verify a program is operating within the legal pathway

Frequently asked questions

Is compounded tirzepatide legal in 2026?
Yes, when prescribed by a licensed clinician and dispensed by a 503A licensed compounding pharmacy or a 503B FDA-registered outsourcing facility, in accordance with Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act. Compounded tirzepatide is not FDA-approved as a finished drug product, but the compounding pathway itself is legal under federal law.
What changed in April 2026?
On April 30, 2026, the FDA published a proposed rulemaking related to the 503B Bulks List. The proposal addresses which active pharmaceutical ingredients (APIs) can be used by 503B outsourcing facilities for compounding. The proposed rule and its public comment period are documented in the Federal Register (docket 2026-08552). Public comment closes June 29, 2026. The rulemaking does not retroactively make existing compliant 503A prescriptions illegal.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No. Mounjaro® and Zepbound® are the only FDA-approved tirzepatide products, both manufactured by Eli Lilly and Company. Compounded tirzepatide is made by 503A pharmacies or 503B outsourcing facilities from tirzepatide API and is not FDA-approved. The active molecule is the same; the regulatory status, finished-product approval, and supply chain differ.
What is a 503A pharmacy?
A 503A pharmacy is a state-licensed compounding pharmacy that compounds patient-specific prescriptions under Section 503A of the FD&C Act. 503A pharmacies operate under USP <797> sterile compounding standards and are accredited by organizations like PCAB.
What is a 503B outsourcing facility?
A 503B is a manufacturer registered with the FDA as an outsourcing facility under Section 503B of the FD&C Act, operating under current Good Manufacturing Practices (cGMP). 503Bs can produce compounded medications in larger quantities for office-use distribution, with FDA inspection.
Where does this leave patients?
Patients with active prescriptions through reputable 503A or 503B pathways can continue receiving compounded tirzepatide under federal law. Patients should: confirm their provider is using a named 503A or 503B partner with current licensing; understand that compounded tirzepatide is not FDA-approved; and monitor FDA developments through the program's published news updates.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

  1. FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
  3. Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
  5. Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Is Compounded Tirzepatide Legal in 2026?.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/is-compounded-tirzepatide-legal.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.